BioGenex, a company focused on molecular pathology and cancer diagnostics, has announced the released of two new antibodies designed to improve cancer diagnosis.
The new antibodies against PMS2 (clone EP51) and CK5 (clone EP24) are being offered alongside BioGenex’ pre-treatment reagents, detection systems and validated protocols for intense staining used to differentiate details within tissue samples.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Carriers of the mismatch repair gene mutations have a high lifetime risk of developing Hereditary Non-Polyposis Colon Cancer (HNPCC) and several other cancers, including endometrial cancer.
“We are pleased to add these two state of the art antibodies to our portfolio of more than 400 IHC [immunohistochemistry] antibodies, reagents and automation systems for pathologists around the world,” said BioGenex CEO, Dr. Krishan Kalra, in a company statement. “We guarantee the performance of our products throughout their shelf-life and are committed to providing premier after-sales support and service for complete customer satisfaction.”
Photo: Screenshot via BioGenex